Different sensitivities of senescent breast cancer cells to immune cell‐mediated cytotoxicity
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Different sensitivities of senescent breast cancer cells to immune cell‐mediated cytotoxicity
Authors
Keywords
-
Journal
CANCER SCIENCE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-06-28
DOI
10.1111/cas.14116
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
- (2018) Mary E. Klein et al. CANCER CELL
- The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
- (2018) David A. Schaer et al. Cell Reports
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment
- (2018) Jessica L.F. Teh et al. CLINICAL CANCER RESEARCH
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant and Adjuvant Therapies for Breast Cancer
- (2017) Susmitha Apuri SOUTHERN MEDICAL JOURNAL
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
- (2017) et al. JAMA Oncology
- Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant
- (2017) Marisa Simon et al. PLoS One
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Premature aging/senescence in cancer cells facing therapy: good or bad?
- (2015) Llilians Calvo Gonzalez et al. BIOGERONTOLOGY
- Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer
- (2015) J. Peng et al. CANCER RESEARCH
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- The Role of CDK4/6 Inhibition in Breast Cancer
- (2015) C. G. Murphy et al. ONCOLOGIST
- Chemotherapy-induced myeloid suppressor cells and antitumor immunity: The Janus face of chemotherapy in immunomodulation
- (2014) Zhi-Chun Ding et al. OncoImmunology
- Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings
- (2013) T. M. A. Abdel-Fatah et al. ANNALS OF ONCOLOGY
- Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8
- (2013) Z. C. Hartman et al. CANCER RESEARCH
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Aging, Cellular Senescence, and Cancer
- (2012) Judith Campisi Annual Review of Physiology
- Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
- (2012) Oktay Tacar et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression
- (2010) Jean-Philippe Coppé et al. Annual Review of Pathology-Mechanisms of Disease
- Therapy-Induced Senescence in Cancer
- (2010) Jonathan A. Ewald et al. JNCI-Journal of the National Cancer Institute
- Mcl-1: A Gateway to TRAIL Sensitization
- (2008) S.-H. Kim et al. CANCER RESEARCH
- Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network
- (2008) Thomas Kuilman et al. CELL
- Chemokine Signaling via the CXCR2 Receptor Reinforces Senescence
- (2008) Juan C. Acosta et al. CELL
- Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
- (2008) Jean-Philippe Coppé et al. PLOS BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now